Skip to main content

Table 3 Response to trabectedin according to the line of treatment

From: Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

  Best response to trabectedine Total
    NE PD SD PR
Line of treatment 1 N 0 3 4 3 10
   % ,0% 30,0% 34,0% 30,0% 100,0%
  2 N 1 32 26 8 67
   % 1,5% 47,8% 38,8% 11,9% 100,0%
  3 N 4 26 27 3 60
   % 6,7% 43,3% 45,0% 5,0% 100,0%
  4 N 4 22 12 4 42
   % 9,5% 52,4% 28,6% 9.5% 100,0%
Total N 9 83 69 18 179
   % 5,0% 46,4% 38,5% 10,1% 100,0%